MicroRNA-130a attenuates cardiac fibrosis after myocardial infarction through TGF-β/Smad signaling by directly targeting TGF-β receptor 1

References

• Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factor. Circ Res. 2017;121:677–694.
   PubMed Web of Science ®Google Scholar
• Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646–659.
   PubMed Web of Science ®Google Scholar
• González A, Schelbert EB, Díez J, et al. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71(15):1696–1706.
   PubMed Web of Science ®Google Scholar
• Pinto AR, Ilinykh A, Ivey MJ, et al. Revisiting cardiac cellular composition. Circ Res. 2016;118:400–409.
   PubMed Web of Science ®Google Scholar
• Porter KE. Turner, Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. N.A;123(2009):255–278.
   PubMed Web of Science ®Google Scholar
• Lobe GECB. ROLE OF T RANSFORMING G ROWTH FACTOR b IN HUMAN DISEASE. N Engl J Med. 2000;100:471–477.
   Google Scholar
• Khalil H, Kanisicak O, Prasad V, et al. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127(10):3770–3783.
   PubMed Web of Science ®Google Scholar
• Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling, cardiovasc. Res. 2007;74:184–195.
   Google Scholar
• Van Rooij E. The art of MicroRNA research. Circ Res. 2011;108:219–234.
   PubMed Web of Science ®Google Scholar
• Van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest. 2007;117(9):2369–2376.
   PubMed Web of Science ®Google Scholar
• Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;2(2):17–19.
   Web of Science ®Google Scholar
• Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124(14):1537–1547.
   PubMed Web of Science ®Google Scholar
• Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613–618.
   PubMed Web of Science ®Google Scholar
• Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114:434–443.
   PubMed Web of Science ®Google Scholar
• da Zhang H, Hong Jiang L, Wei Sun D, et al. The role of miR-130a in cancer. Breast Cancer. 2017;24(4):521–527.
   PubMed Web of Science ®Google Scholar
• Luo H, Chen B, Weng B, et al. miR-130a promotes immature porcine Sertoli cell growth by activating SMAD5 through the TGF-β-PI3K/AKT signaling pathway. FASEB J. 2020;34(11):15164–15179.
   PubMed Web of Science ®Google Scholar
• Zheng T, Shi Y, Zhang J, et al. MiR-130a exerts neuroprotective effects against ischemic stroke through PTEN/PI3K/AKT pathway. Biomed Pharmacother. 2019;117:109117.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang H, Zhou, J. MiR-130a-3p, a Preclinical Therapeutic Target for Crohn’s Disease. J Crohn’s Colitis. 2021;15:647–664. DOI:10.1093/ecco.
   Google Scholar
• Su S, Zhao Q, He C, et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun. 2015;6(1):1–19.
   Web of Science ®Google Scholar
• Ai K, Zhu X, Kang Y, et al. miR-130a-3p inhibition protects against renal fibrosis in vitro via the TGF-β1/Smad pathway by targeting SnoN. Exp Mol. Pathol. 2020;112. 10.1016/j.yexmp.2019.104358.
   Google Scholar
• Liu L, Wang P, Wang YS, et al. MiR-130a-3p alleviates liver fibrosis by suppressing HSCs activation and skewing macrophage to Ly6Clo Phenotype. Front Immunol. 2021;12:1–15.
   Web of Science ®Google Scholar
• Zhou T, Qin G, Yang L, et al. LncRNA XIST regulates myocardial infarction by targeting miR-130a-3p. J Cell Physiol. 2019;234(6):8659–8667.
   PubMed Web of Science ®Google Scholar
• Gao E, Lei YH, Shang X, et al. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res. 2010;107:1445–1453.
   PubMed Web of Science ®Google Scholar
• Yang M, Song L, Wang L, et al. Deficiency of GATA3-positive macrophages improves cardiac function following myocardial infarction or pressure overload hypertrophy. J Am Coll Cardiol. 2018;72(8):885–904.
   PubMed Web of Science ®Google Scholar
• Takagawa J, Zhang Y, Wong ML, et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol. 2007;102(6):2104–2111.
   PubMed Web of Science ®Google Scholar
• Viereck J, Kumarswamy R, Foinquinos A, et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci. Transl. Med. 2016;8:1–13.
   Web of Science ®Google Scholar
• Huang ZP, Young Seok H, Zhou B, et al. CIP, a cardiac isl1-interacting protein, represses cardiomyocyte hypertrophy. Circ Res. 2012;110:818–830.
   PubMed Web of Science ®Google Scholar
• Lee TH, Yeh CF, Lee YT, et al. Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFβ signaling through TGFBR1 stabilization. Nat Commun. 2020;11. DOI:10.1038/s41467-020-18047-x.
   Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–1816.
   PubMed Web of Science ®Google Scholar
• Van Den Borne SWM, Diez J, Blankesteijn WM, et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7(1):30–37.
   PubMed Web of Science ®Google Scholar
• Virag JI, Murry CE. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol. 2003;163(6):2433–2440.
   PubMed Web of Science ®Google Scholar
• Driesen RB, Nagaraju CK, Abi-Char J, et al. Reversible and irreversible differentiation of cardiac fibroblasts. Cardiovasc Res. 2014;101:411–422.
   PubMed Web of Science ®Google Scholar